Drug intelligence / Profile preview

artemisinin

Development stage
Phase 4
Lead developer
Ping Hau Sau Res Group
Modality
Small Molecules
Administration
Oral, Intramuscular, Rectal
01

Overview

Artemisinin is a sesquiterpene lactone with an unusual endoperoxide bridge that is responsible for its potent antimalarial activity. It is a natural product isolated from the plant Artemisia annua (sweet wormwood), traditionally used in Chinese medicine. Discovered by Tu Youyou in 1972, artemisinin and its derivatives have become the cornerstone of malaria treatment worldwide—especially for Plasmodium falciparum infections and cases resistant to other antimalarials. Artemisinin acts as a prodrug; after administration it is converted to dihydroartemisinin inside erythrocytes. The drug’s endoperoxide ring reacts with iron(II) within heme or hemozoin in infected red blood cells, generating free radicals that damage parasite proteins and lead to rapid parasite death. Artemisinin-based combination therapies (ACTs) are now standard of care due to concerns about resistance when used as monotherapy. Besides malaria, artemisinin has shown activity against other protozoal infections and has been investigated for potential anticancer effects[1][3][5][7][10].

Other names
qinghaosu青蒿素artemisininahuanghuahaosuarteannuinartemisinine
02

Targets

Heme

Beyond the preview

Go deeper on artemisinin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on artemisinin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call